Quotient Ltd. (NASDAQ:QTNT) saw unusually-high trading volume on Wednesday . Approximately 190,635 shares traded hands during mid-day trading, an increase of 272% from the previous session’s volume of 51,234 shares.The stock last traded at $6.13 and had previously closed at $6.17.

QTNT has been the subject of several research analyst reports. Zacks Investment Research cut Quotient from a “hold” rating to a “sell” rating in a research note on Thursday, June 9th. Jefferies Group restated a “buy” rating and issued a $28.00 price objective on shares of Quotient in a research note on Wednesday, June 1st.

The company’s market capitalization is $88.12 million. The firm’s 50-day moving average is $6.56 and its 200 day moving average is $8.40.

In related news, insider D J. Paul E. Cowan purchased 45,455 shares of the business’s stock in a transaction on Wednesday, August 3rd. The shares were bought at an average price of $5.50 per share, for a total transaction of $250,002.50. Following the acquisition, the insider now directly owns 26,666 shares in the company, valued at $146,663. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Unger sold 14,484 shares of the company’s stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $9.99, for a total value of $144,695.16. The disclosure for this sale can be found here.

Quotient Limited is a commercial-stage diagnostics company. The Company is focused on blood grouping and serological disease screening. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood, which includes antigen typing and antibody identification.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.